Moderna (MRNA) Other Accumulated Expenses (2017 - 2026)

Moderna (MRNA) has reported Other Accumulated Expenses for 10 consecutive years, with $163.0 million the latest figure, recorded in Q2 2026.

• On a quarterly basis, Other Accumulated Expenses fell 15.1% year-over-year to $163.0 million in Q2 2026; TTM through Jun 2026 was $163.0 million, a 15.1% decrease from a year earlier, with the FY2025 full-year figure at $185.0 million, down 16.29% from the prior year.
• Other Accumulated Expenses was $163.0 million for Q2 2026 at Moderna, down from $220.0 million in the prior quarter.
• Over five years, Other Accumulated Expenses peaked at $553.0 million in Q3 2022 and troughed at $42.0 million in Q2 2024.
• A 5-year average of $215.2 million and a median of $216.0 million in 2023 frame the typical range for Other Accumulated Expenses.
• Across the five-year window, Other Accumulated Expenses sank 82.2% in 2024 and soared 357.14% in 2025, its largest moves.
• Over 5 years, Other Accumulated Expenses stood at $249.0 million in 2022, then slumped by 48.19% to $129.0 million in 2023, then soared by 71.32% to $221.0 million in 2024, then fell by 16.29% to $185.0 million in 2025, then declined by 11.89% to $163.0 million in 2026.
• The last three Other Accumulated Expenses figures came in at $163.0 million (Q2 2026), $220.0 million (Q1 2026), and $185.0 million (Q4 2025), per Business Quant data.